Kanabo Group plc (LSE: KNB), a patient-focused Healthtech company, has launched Treat It, a new online medicinal cannabis clinic for pain management.

The new clinic aims to address the issue of limited access to pain management treatments for the approximately 8 million chronic pain sufferers in the UK. These individuals face difficulties accessing medical treatments due to long waiting times, bureaucracy, and affordability. According to recent data, 24% of chronic pain sufferers in the UK are currently being prescribed opioids, making up approximately 3 million of the potential patients who can benefit from switching to medicinal cannabis.

Treat It enables patients to access healthcare professionals via Kanabo's secure, digital healthcare platform. It will be focused on secondary care, including the prescription of medicinal cannabis. Studies have shown that medicinal cannabis can relieve pain for a range of common chronic pain conditions. Kanabo's existing online clinic, The GP Service, offers patients access to experienced healthcare professionals who can offer a broad range of treatment recommendations for primary care.

The growing demand for pain management treatments using medicinal cannabis is reflected in the increase in medical cannabis prescriptions issued in the UK, with over 89,000 issued between November 2018 and July 2022, indicating an average growth rate of approximately 72% per year, with more than 100% growth in 2022.

Avihu Tamir, CEO of Kanabo Group said: 'Our innovative healthcare platform, Treat It, seeks to directly address the limited access to pain management treatments for patients across the UK. Leveraging our proprietary technology from The GP Service, which we have recently integrated, we have created an online ecosystem for chronic pain sufferers, providing access to doctors and medicinal cannabis prescriptions. Our goal is to offer patients direct access to high-quality medical treatments; empowering patients to take control of their own personalised care.'

Treat It forms part of the Company's growing technology stack, and combines proprietary digital tools and a treatment portfolio, including patient access, online consultations, prescriptions, and medication dispensing, into an integrated end-to-end solution. This unified approach offers patients efficient and effective access to qualified medical practitioners. Kanabo's treatment portfolio focuses on pain management using medications and treatments, including medicinal cannabis, which is currently unavailable through traditional channels. However, demand for these products is growing as patients seek alternative pain management options.

Treat It is regulated by The Care Quality Commission and certified with ISO 27001 for information security, will allow doctors registered with the General Medical Council to prescribe medicinal cannabis to patients while following the guidelines set out by the National Institute for Health and Care Excellence.

Contact:

Avihu Tamir

Tel: +44 (0)20 7390 0230

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a Healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

(C) 2023 Electronic News Publishing, source ENP Newswire